EUVIMEDEUVIMED entdecken
Crossref

Protective effects of 23‐valent pneumococcal polysaccharide vaccination against mortality among elder patients with type 2 diabetes mellitus

Xiaoling Peng, Shujun Gu, Jingchao Liu, Deqi Kong, Guorong Yang, Ran Guo, Chaoqun Xu, Xulei Hu, Qiang Li, He Yang, Ning Zhang, Chen Dong iD

Diabetic Medicine · 2026

DOI: 10.1111/dme.70341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetic Medicine, 2026. Verfasst von Xiaoling Peng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Statistics, School of Public Health, Medical College of Soochow University, Soochow, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Pneumococcal Vaccines, Pneumococcal Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Key Projects of Changshu Health Commission, the Key technologies of prevention and control of major diseases and infectious diseases in Suzhou City, the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Older adults with type 2 diabetes mellitus are at elevated risk for severe pneumococcal disease, experiencing higher rates of complications and mortality. However, the evidence for the protective benefits of the 23‐valent pneumococcal polysaccharide vaccine (PPSV23) against mortality in this demographic remains limited.

Methods

This retrospective study included 8649 elderly people with type 2 diabetes mellitus in Soochow, China, comprising 3247 PPSV23‐vaccinated individuals and 5402 unvaccinated patients. Cox proportional hazards analyses were performed to calculate the adjusted hazard ratios (HRs) of the association between PPSV23 vaccination and the risk of all cause mortality, pneumonia‐related mortality, cardiovascular disease‐related mortality and cancer mortality. Inverse probability weighting (IPW) was applied to estimate the average treatment effect (ATE) of universal PPSV23 vaccination compared to unvaccinated.

Results

During the follow‐up period, a total of 1557 deaths were recorded. Compared to unvaccinated elderly people with type 2 diabetes mellitus, those receiving PPSV23 vaccine exhibited significantly lower risks of all‐cause mortality (HR: 0.47; 95% CI: 0.42–0.53), with reductions also observed in deaths related to cardiovascular disease (HR: 0.50; 95% CI: 0.41–0.62), pneumonia (HR: 0.62; 95% CI: 0.43–0.89) and cancer (HR: 0.54; 95% CI: 0.42–0.70). Furthermore, IPW estimates indicated that universal PPSV23 vaccination among the elderly people with type 2 diabetes mellitus could prevent an average of 11.4% of all‐cause deaths ( p < 0.001), 4.0% of cardiovascular disease‐related deaths ( p < 0.001), 0.8% of pneumonia‐related deaths ( p = 0.005) and 1.9% of cancer deaths ( p < 0.001).

Conclusions

PPSV23 vaccination is associated with a reduced risk of all cause mortality, cardiovascular disease‐related mortality, pneumonia‐related mortality and cancer mortality in elderly people with type 2 diabetes mellitus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Pneumococcal VaccinesPneumococcal InfectionsHumansFemaleAgedMaleRetrospective StudiesAged, 80 and overChinaCardiovascular DiseasesVaccinationPneumonia, PneumococcalUnvaccinated Persons

Stichwörter der Autor:innen

PPSV23average treatment effectmortalitytype 2 diabetes mellitus

Substanzen

Pneumococcal Vaccines23-valent pneumococcal capsular polysaccharide vaccine

Autor:innen und Institutionen

  • Department of Epidemiology and Statistics, School of Public Health, Medical College of Soochow University, Soochow, China.
  • Department of Immunization, Changshu Center for Disease Control and Prevention, Soochow, China.
  • Department of Immunization, Wuzhong Center for Disease Control and Prevention, Soochow, China.

ORCID-Profile: Chen Dong

Förderung

  • Key Projects of Changshu Health Commission
  • the Key technologies of prevention and control of major diseases and infectious diseases in Suzhou City
  • the National Natural Science Foundation of China

Zitieren

APA

Peng, X., Gu, S., Liu, J., Kong, D., Yang, G., Guo, R., Xu, C., Hu, X., Li, Q., Yang, H., Zhang, N., & Dong, C. (2026). Protective effects of 23‐valent pneumococcal polysaccharide vaccination against mortality among elder patients with type 2 diabetes mellitus. Diabetic Medicine. https://doi.org/10.1111/dme.70341

Vancouver

Peng X, Gu S, Liu J, Kong D, Yang G, Guo R, et al. Protective effects of 23‐valent pneumococcal polysaccharide vaccination against mortality among elder patients with type 2 diabetes mellitus. Diabetic Medicine. 2026. doi:10.1111/dme.70341

BibTeX
@article{Peng2026,
  author = {Peng, Xiaoling and Gu, Shujun and Liu, Jingchao and Kong, Deqi and Yang, Guorong and Guo, Ran and Xu, Chaoqun and Hu, Xulei and Li, Qiang and Yang, He and Zhang, Ning and Dong, Chen},
  title = {Protective effects of 23‐valent pneumococcal polysaccharide vaccination against mortality among elder patients with type 2 diabetes mellitus},
  journal = {Diabetic Medicine},
  year = {2026},
  doi = {10.1111/dme.70341}
}
Kostenlos starten →